STRING | IntAct | MINT

Open Targets | OMIM

Catalytic Site Atlas

-

Isoform 1: Nucleus,Cytoplasm,Cell membrane;Isoform 3: Nucleus,Cytoplasm,Cell membrane,Cell membrane;Nucleus,Golgi apparatus,Cell membrane;

Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.

GO:0005737; GO:0005829; GO:0005794; GO:0016021; GO:0016020; GO:0000790; GO:0005654; GO:0005634; GO:0005886; GO:0032991; GO:0097550; GO:0035327; GO:0051117; GO:0008013; GO:0003682; GO:0001228; GO:0003700; GO:0000981; GO:0019899; GO:0030284; GO:0030331; GO:0034056; GO:0042802; GO:0030235; GO:0004879; GO:0046934; GO:0019901; GO:0000978; GO:0005496; GO:0017025; GO:0001093; GO:0001223; GO:0008134; GO:0008270; GO:0008209; GO:0001547; GO:0071392; GO:0071391; GO:0006338; GO:0002064; GO:0060750; GO:0030520; GO:0030518; GO:0008584; GO:0060749; GO:0060745; GO:0043433; GO:0010629; GO:0043124; GO:1903799; GO:0000122; GO:0007200; GO:0007204; GO:0051091; GO:0048146; GO:0045429; GO:0051000; GO:0010863; GO:0051897; GO:0045899; GO:0045944; GO:0045893; GO:0060527; GO:0060523; GO:0016579; GO:0071168; GO:0042981; GO:0060687; GO:0050727; GO:0033146; GO:0034121; GO:0006357; GO:0006355; GO:0030111; GO:0032355; GO:0043627; GO:0007165; GO:0048863; GO:0006366; GO:0006367; GO:0006351; GO:0060065; GO:0060068